Article Text

Original research
Novel IL-4/HB-EGF-dependent crosstalk between eosinophils and macrophages controls liver regeneration after ischaemia and reperfusion injury
  1. Yang Yang1,
  2. Long Xu1,
  3. Constance Atkins1,
  4. Lily Kuhlman2,
  5. Jie Zhao1,
  6. Jong-Min Jeong1,
  7. Yankai Wen2,
  8. Nicolas Moreno1,
  9. Kang Ho Kim1,
  10. Yu A An1,
  11. Fenfen Wang1,
  12. Steve Bynon3,
  13. Vincenzo Villani3,
  14. Bin Gao4,
  15. Frank Brombacher5,
  16. Raymond Harris6,
  17. Holger K Eltzschig1,
  18. Elizabeth Jacobsen7,
  19. Cynthia Ju1
  1. 1Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
  2. 2The University of Texas Health Science Center at Houston, Houston, TX, USA
  3. 3Department of Surgery, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA
  4. 4Laboratory of Liver Disease, National Institute on Alcohol Abuse and Alcoholism, NIH, Bethesda, MD, USA
  5. 5University of Cape Town Faculty of Health Sciences, Observatory, Western Cape, South Africa
  6. 6Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA
  7. 7Division of Allergy, Asthma and Clinical Immunology, Mayo Clinic Arizona, Scottsdale, AZ, USA
  1. Correspondence to Dr Cynthia Ju, Department of Anesthesiology, Critical Care and Pain Medicine, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA; changqing.ju{at}uth.tmc.edu

Abstract

Objective Previous studies indicate that eosinophils are recruited into the allograft following orthotopic liver transplantation and protect from ischaemia reperfusion (IR) injury. In the current studies, we aim to explore whether their protective function could outlast during liver repair.

Design Eosinophil-deficient mice and adoptive transfer of bone marrow-derived eosinophils (bmEos) were employed to investigate the effects of eosinophils on tissue repair and regeneration after hepatic IR injury. Aside from exogenous cytokine or neutralising antibody treatments, mechanistic studies made use of a panel of mouse models of eosinophil-specific IL-4/IL-13-deletion, cell-specific IL-4rα-deletion in liver macrophages and hepatocytes and macrophage-specific deletion of heparin-binding epidermal growth factor-like growth factor (hb-egf).

Result We observed that eosinophils persisted over a week following hepatic IR injury. Their peak accumulation coincided with that of hepatocyte proliferation. Functional studies showed that eosinophil deficiency was associated with a dramatic delay in liver repair, which was normalised by the adoptive transfer of bmEos. Mechanistic studies demonstrated that eosinophil-derived IL-4, but not IL-13, was critically involved in the reparative function of these cells. The data further revealed a selective role of macrophage-dependent IL-4 signalling in liver regeneration. Eosinophil-derived IL-4 stimulated macrophages to produce HB-EGF. Moreover, macrophage-specific hb-egf deletion impaired hepatocyte regeneration after IR injury.

Conclusion Together, these studies uncovered an indispensable role of eosinophils in liver repair after acute injury and identified a novel crosstalk between eosinophils and macrophages through the IL-4/HB-EGF axis.

  • ischaemia-reperfusion
  • immunology in hepatology
  • growth factors
  • macrophages
  • liver regeneration

Data availability statement

Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

http://creativecommons.org/licenses/by-nc/4.0/

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Video Abstract

Disclaimer: this video summarises a scientific article published by BMJ Publishing Group Limited (BMJ). The content of this video has not been peer-reviewed and does not constitute medical advice. Any opinions expressed are solely those of the contributors. Viewers should be aware that professionals in the field may have different opinions. BMJ does not endorse any opinions expressed or recommendations discussed. Viewers should not use the content of the video as the basis for any medical treatment. BMJ disclaims all liability and responsibility arising from any reliance placed on the content.

WHAT IS ALREADY KNOWN ON THIS TOPIC

  • Eosinophils are rapidly recruited to the liver in response to acute injuries and exert a protective role.

  • Recent studies highlighted previously unrecognised functions of eosinophils in resolving inflammation and promoting tissue repair.

  • Interleukin (IL)-4 is known to induce alternative activation of macrophages; however, the downstream target involved in macrophage-mediated liver repair is unclear.

WHAT THIS STUDY ADDS

  • Demonstrates that eosinophils play an indispensable role in promoting liver repair and regeneration after acute injuries.

  • Identifies the selective role of IL-4, but not IL-13, in mediating the reparative function of eosinophils.

  • Reveals a novel and essential crosstalk between eosinophils and macrophages, through the IL-4/IL-4Rα/HB-EGF axis, during liver repair and regeneration.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

  • Opens up new avenues for research of eosinophil functions in liver pathophysiological conditions.

  • Inspires further exploration of eosinophils and/or the IL-4/HB-EGF pathway as therapies to accelerate liver recovery after acute injuries.

  • Identifies molecular and cellular targets for the development of strategies to expand donor organ pools for liver transplantation.

Introduction

Liver transplantation is the only viable treatment for acute liver failure and end-stage chronic liver disease.1 2 Hepatic ischaemia reperfusion (IR) injury, which occurs during transplantation surgery, is a major factor contributing to acute liver dysfunction and long-term complications, including graft rejection.3 4 In the USA, there is a significant shortage of donor organs, resulting in approximately 15% yearly mortality of patients waiting for liver transplantation.5 The increasing demand for liver grafts has led to more frequent use of ‘marginal’ organs, such as those from older, steatotic and deceased after circulatory death donors.6 Unfortunately, ‘marginal’ livers are highly susceptible to IR injury, resulting in delayed and poor recovery of the grafts.7 8 Studies of hepatic IR injury have focused mainly on the injury phase.9–17 There is a critical need to identify molecular and cellular players key to liver repair and regeneration after IR injury.

Eosinophils are a subset of bone marrow-derived granular myeloid cells. The understanding of eosinophil functions has been updated from perceiving them solely as effector cells involved in parasitic infections18 19 and allergic responses20–22 to recognising that they are regulators of Local Immunity And/or Remodelling/Repair in both health and disease.23 Recent emerging studies have highlighted previously unrecognised functions of eosinophils in resolving inflammation and promoting tissue repair. For instance, in acute peritonitis, eosinophils accumulate in the inflamed foci and produce anti-inflammatory and pro-resolving cytokines and lipid mediators.24 25 In response to cardiotoxin-induced acute skeletal muscle injury, eosinophils rapidly infiltrate the injured tissue and promote fibrogenic/adipogenic progenitor cell proliferation, thereby facilitating muscle regeneration.26 Another study showed eosinophils play an important role in endometrial stromal cell proliferation, proving crucial in tissue repair after infection.27 Most recently, three studies demonstrated the essential role of eosinophils in cardiac healing after myocardial infarction.28–30

We previously reported that eosinophils were rapidly recruited to the liver following orthotopic liver transplantation in humans and after hepatic IR injury in mice. These cells attenuated injury, through suppressing neutrophils, during the first 24 hours (injury phase) after hepatic IR surgery.31 Surprisingly, we observed that eosinophils continue to accumulate in the liver beyond the injury phase, with peak accumulation coinciding with the hepatocyte proliferation phase. Using strains of constitutive and inducible eosinophil-deficient mice and an adoptive cell transfer approach, we uncovered an essential role of eosinophils in tissue repair after hepatic IR injury. The data elucidated a novel underlying mechanism involving eosinophil-macrophage crosstalk via an IL-4/HB-EGF-mediated axis.

Results

Eosinophil accumulation in the liver persists during liver repair following hepatic IR injury

Our previous study demonstrated that eosinophils were recruited to the liver within the first 24 hours after hepatic IR injury in mice and exerted a profound protective effect.31 Surprisingly, when we examined the kinetics of eosinophil accumulation, we observed that these cells persisted in the liver beyond the injury phase. Eosinophils were identified as CD45+CD11b+Ly6GSSChighSiglec-F+CCR3+ cells by flow cytometry. Additionally, immunohistochemical staining was conducted to detect eosinophils using an antibody recognising major basic protein (a generous gift from Dr Elizabeth Jacobsen, Mayo Clinic, Arizona, USA).32 33 Compared with sham mice, those subjected to IR injury had elevated accumulation of eosinophils in the liver up to 5 days after IR injury, with a peak on day 3 (figure 1A–E), coinciding with the peak of hepatocyte proliferation in wild-type C57Bl/6J (WT) mice (figure 1F,G). These data suggested that eosinophils might contribute to liver repair and regeneration after IR injury.

Figure 1

The kinetics of hepatic eosinophil accumulation and the time course of liver repair after IR injury in WT mice. Male C57Bl/6J mice were subjected to hepatic ischemia (60 mins) followed by reperfusion and sacrificed at various times (n=3/group). Sham mice underwent the same surgery without vascular blockage and were sacrificed on day 7. (A-C) The percentage and numbers of eosinophils (CD45+CD11b+Ly6G-Siglec-F+CCR3+cells) in the liver were measured by flow cytometry and quantified. (D, E) IHC staining for eosinophils by anti-mouse major basic protein (MBP) antibody and the numbers of MBP+ cells quantified. (F, G) Proliferating hepatocytes were stained by anti-Ki67 antibody, and the numbers of positive cells were quantified. (H, I) Liver necrosis (N, outlined areas) was evaluated and quantified. (J) Liver pathology was assessed by using the Suzuki’s scoring system. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in B, C, E, G, I and J.

Eosinophils play an indispensable role in tissue repair after hepatic IR injury

By day 7 after IR injury, the liver nearly completely recovered in WT mice, based on the quantification of necrotic areas and the Suzuki scores (figure 1H–J). To determine the role of eosinophils in liver repair, we used two strains of eosinophil-deficient mice (ΔdblGATA1 and PHIL mice). Compared with WT mice, extensive areas of necrosis (>30% of the liver) remained in both strains on day 7 after IR injury (online supplemental figure S1B–D, F–H). However, one caveat in interpreting the data is that eosinophil-deficient mice had much more severe liver IR injury (online supplemental figure S1A,E), which could contribute to delayed tissue repair. To circumvent this issue, we used inducible eosinophil-deficient (iPHIL) mice, which were generated by knocking-in the human diphtheria toxin (DT) receptor gene into the endogenous eosinophil peroxidase genomic locus.34 We first established a DT dosing regimen that can achieve eosinophil depletion. The data demonstrated that after two consecutive injections of DT on day 1 and day 2, the number of eosinophils in the blood reduced markedly on day 3 and maintained at low levels of abundance until at least day 8 (online supplemental figure S2A). Based on these results, we administered the first dose of DT to iPHIL mice and WT littermates 16 hours prior to hepatic ischaemia surgery and injected the second dose 6 hours after surgery (figure 2A). This protocol ensured comparable hepatic IR injury between DT-treated WT littermates and iPHIL mice (online supplemental figure S2B) and achieved successful depletion of eosinophils in iPHIL mice after injury and during the time of repair (online supplemental figure S2C,D). We observed a significant delay in tissue repair in iPHIL mice compared with WT littermates, evidenced by larger areas of necrosis and higher Suzuki scores on day 7 after IR surgery (figure 2B–D). These changes coincided with the dramatic reduction of hepatocyte proliferation markers (Ki67 and proliferating cell nuclear antigen (PCNA)) on day 3 (figure 2E–H).

Supplemental material

Figure 2

Eosinophils promote liver repair after IR injury. (A-H) Male iPHIL mice and WT littermates were subjected to hepatic IR surgery. Mice were administered (i.p.) the first dose of DT at 16h prior to IR surgery and the second dose at 6h after surgery. Mice were sacrificed on day 3 (n=4/group) or day 7 (n=6/group) after IR surgery. (B, C) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (D) Liver pathology was determined by the Suzuki score on day 7 after IR surgery. (E, F) Liver tissue sections were stained for Ki67 to quantify proliferating hepatocytes on day 3 after IR surgery. (G, H) PCNA protein expression was detected by Western blotting and quantified. (I-P) Male ΔdblGATA-1 mice were subjected to hepatic IR surgery. After 24h, half of the mice were i.v. injected with bmEos (10x106) and the other half injected with saline as control. Mice were sacrificed on day 3 (n=4/group) or day 7 after IR surgery (n=6/group). (J, K) Liver necrosis (N, outlined area) was evaluated and quantified on day 7 after IR surgery. (L) Liver pathology was determined by the Suzuki score on day 7 after IR surgery. (M, N) Proliferative hepatocytes were stained for Ki67 and quantified on day 3 after IR surgery. (O, P) PCNA protein expression was detected by Western blotting and quantified. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in C, D, F, H, K, L, N and P.

To further investigate the role of eosinophils in liver repair, we adoptively transferred bmEos to eosinophil-deficient mice after IR injury (figure 2I). To evaluate the feasibility, we prepared bmEos from B6-CD45.1 mice and intravenously injected to C57Bl/6J (B6-CD45.2) recipients and tracked the cells by flow cytometry. The data showed rapid infiltration of CD45.1+bmEos into the recipient’s liver within 30 min, reaching its peak at 6 hours postinjection and persisting for at least 3 days postinjection (online supplemental figure S3A,B). After validating the protocol, we adoptively transferred bmEos from WT mice (WT-bmEos) to ΔdblGATA1 and PHIL mice on day 1 after IR surgery. We used this time point to avoid the effects of WT-bmEos on the extent of injury. As shown in figure 2J–L and online supplemental figure S4A–C, while large areas of necrosis remained after IR surgery in control eosinophil-deficient mice injected with saline, liver histology returned to nearly normal in those that received WT-bmEos. Moreover, hepatocyte proliferation was restored in ΔdblGATA1 mice injected with WT-bmEos (figure 2M–P).

To further validate the pro-repair function of eosinophils, we extended the study to two additional models of acute liver injury caused by acetaminophen (APAP) or carbon tetrachloride (CCl4). We treated iPHIL mice and their WT littermates with DT 16 hours before and 8 hours after APAP or CCl4 challenge. As shown in online supplemental figure S5, the WT and iPHIL mice developed similar degrees of liver injury. However, in both acute liver injury models, a significant delay in tissue recovery was observed in iPHIL mice compared with WT littermates. This was evidenced by the presence of larger areas of necrosis and higher Suzuki scores on day 6 after APAP or CCl4 treatment. Together, these data provide strong evidence that eosinophils play an essential role in the liver repair process after acute injury.

To understand how eosinophils promote liver repair after IR injury, we performed a cytokine array analysis (Proteome Profiler Mouse Cytokine Array Kit). The data demonstrated IL-4 and IL-13 as the most significantly upregulated cytokines on adoptive transfer of WT-bmEos to ΔdblGATA1 mice (online supplemental figure S6). To further investigate the cellular source of IL-4 and IL-13, we performed flow cytometric analyses using IL-4/GFP-enhanced transcript (4Get) mice to measure IL-4 expression and intracellular staining to detect IL-13. The data showed that eosinophils accounted for >86% of IL-4-positive cells and >90% of IL-13-positive cells in the liver (online supplemental figure S7A,B), suggesting that IL-4 and IL-13 are mainly produced by eosinophils during tissue repair. To investigate the role of eosinophil-derived IL-4 and/or IL-13 in liver repair, we generated mice with eosinophil-specific deletion of both IL-4 and IL-13 (Il-4/13fl/fleoCre+/-). We obtained bmEos from these mice and their WT littermates (Il-4/13fl/fleoCre−/−) and adoptively transferred the cells to ΔdblGATA1 mice on day 1 after hepatic IR injury (figure 3A). While WT-bmEos restored liver repair in ΔdblGATA1 mice, IL-4/13-deleted bmEos failed to improve liver repair compared with control ΔdblGATA1 mice injected with saline (figure 3B–D). Congruent with this observation, the adoptive transfer of WT-bmEos, but not IL-4/13-deleted bmEos, significantly increased hepatocyte proliferation in ΔdblGATA1 mice on day 3 after IR injury (figure 3E,F). These data suggest that eosinophil-derived IL-4 and/or IL-13 are critically involved in liver repair and regeneration after IR injury.

Figure 3

Eosinophil-derived IL-4 plays a critical role in liver repair after IR injury. (A-F) Male ΔdblGATA-1 were subjected to hepatic IR surgery. After 24h, the mice were divided into three groups and i.v. injected with saline, WT-bmEos (10x106) or Il-4/13-deleted bmEos (10x106). Mice were sacrificed on day 3 (n=4/group) or day 7 (n=6/group) after IR surgery. (B, C) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (D) Liver pathology was assessed by using the Suzuki’s scoring system on day 7 after IR surgery. (E, F) Proliferative hepatocytes were stained for Ki67 and quantified on day 3 after IR surgery. (A, G-K) Male ΔdblGATA-1 were subjected to hepatic IR surgery. After 24h, the mice were divided into three groups and i.p. injected with PBS, IL-4c (5 μg recombinant IL-4 complexed to 25 μg anti-IL-4 antibody) or IL-13c (5 µg of recombinant IL-13 complexed to 25 µg anti-IL-13 antibody). Mice were sacrificed on day 3 (n=4/group) or day 7 (n=6/group). (G, H) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (I) Liver pathology was assessed by using the Suzuki’s scoring system quantified on day 7 after IR surgery. (J, K) Proliferative hepatocytes were stained for Ki67 and quantified on day 3. (A, L-P) Male C57Bl/6J mice were subjected to hepatic IR surgery. On day 1 and day 3 after surgery, the mice were i.p. injected with anti-IL-4 antibody (10 μg/mouse) or anti-IL-13 antibody (10 μg/mouse). Control mice were injected with IgG. Mice were sacrificed on day 3 (n=4/group) or day 7 (n=6/group) after IR surgery. (L, M) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (N) Liver pathology was assessed by using the Suzuki’s scoring system on day 7 after IR surgery. (O, P) Proliferative hepatocytes were stained for Ki67 and quantified on day 3. (A, Q-S) Male ΔdblGATA-1 mice were subjected to hepatic IR surgery. After 24h, half of the mice were i.v. injected with WT-bmEos (10x106) and the other half injected with Il-4-deleted bmEos (10x106). Mice were sacrificed on day 7 after IR surgery (n=4/group). (Q, R) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (S) Liver pathology was assessed by using the Suzuki’s scoring system on day 7 after IR surgery. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in R and S. One-way ANOVA was performed in C, D, F, H, I, K, M, N and P.

Eosinophils promote liver tissue repair through IL-4 production

To further determine whether the delayed liver repair in ΔdblGATA1 mice was due to the lack of eosinophil-derived IL-4 or IL-13, we injected IL-4/anti-IL-4 mAb complex (IL-4c) or IL-13/anti-IL-13 mAb complex (IL-13c) to ΔdblGATA1 mice (figure 3A). We used the antibody-conjugated cytokines to prolong the half-life of the cytokines as reported in many studies.35–38 Our data showed that IL-4c injection could significantly increase hepatocyte proliferation (figure 3J,K) and accelerate liver repair (figure 3G–I). Moreover, blockade of IL-4 by a neutralising antibody significantly delayed liver repair in WT mice, as demonstrated by decreased numbers of Ki67+ hepatocytes on day 3 after IR injury as well as increased Suzuki scores and extents of live necrosis on day 7 (figure 3L–P). In contrast, we did not observe any improvement of liver repair in ΔdblGATA1 mice treated with IL-13c, nor any inhibitory effect by IL-13 blockade on liver repair in WT mice (figure 3G–P). To further corroborate these results, we adoptively transferred bmEos obtained from IL-4−/− mice to ΔdblGATA-1 mice on day 1 after IR surgery (figure 3A). Our data showed that IL-4-deleted bmEos, although expressing IL-13, could not restore liver repair in ΔdblGATA1 mice (figure 3Q–S). Taken together, these data strongly suggest that eosinophil-derived IL-4, but not IL-13, plays a critical role in promoting liver regeneration and repair after IR injury.

IL-4Rα signalling in hepatic macrophage orchestrates liver repair after IR injury

The direct effect of IL-4 on hepatocytes has been investigated in the context of liver regeneration after non-injurious partial hepatectomy, but the results are controversial. One study suggested that IL-4 could stimulate hepatocyte proliferation39; however, another study showed that IL-4 did not directly affect hepatocyte proliferation.40 To investigate if hepatocytes are a direct target of IL-4, we generated a mouse line with hepatocyte-specific IL-4rα-deletion (Il-4rαfl/flAlb-Cre+/−). After IR surgery, these mice showed similar degrees of liver injury with no effect on tissue recovery (figure 4A–F). These data ruled out a direct effect of IL-4 on hepatocytes during liver regeneration and repair after IR injury.

Figure 4

IL-4Rα signaling in liver macrophages, rather than hepatocytes, promotes liver repair after IR injury. (A-F) Male Il-4rαfl/flAlb-Cre+/- mice and WT littermates (Male Il-4rαfl/flAlb-Cre-/-) were subjected to hepatic IR surgery and sacrificed after 3 days (n=4/group) or 7 days (n=6/group). (G-L) Male Il-4rα fl/flClec4f-Cre+/- mice and WT littermates (Il-4rαfl/flClec4f-Cre-/-) were subjected to hepatic IR surgery. After 24h, the Il-4rαfl/flClec4f-Cre+/- mice were divided into two groups and injected (i.v.) with PBS or IL-4c (n=6/group) and and sacrificed after 3 days (n=4/group) or 7 days (n=6/group) after IR surgery. (A, G) Serum ALT levels 6h after IR surgery. (B, C, H, I) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (D, J) Liver pathology was assessed by using the Suzuki’s scoring system on day 7 after IR surgery. (E, F, K, L) Proliferative hepatocytes were stained for Ki67 and quantified on day 3 after IR surgery. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in A, C, D, F, G and L. One-way ANOVA was performed in I and J.

To search for IL-4 target cells, we screened for IL-4Rα expression in NPCs. Our data showed that >70% of IL-4Rα-positive cells were macrophages (F4/80+), and the rest were liver sinusoidal endothelial cells (CD31+) (online supplemental figure S8). To further address whether IL-4 promotes liver repair through IL-4Rα signalling in macrophages, we generated macrophage-specific Il-4rα-deleted mice using Clec4f-Cre mice, which have been used to successfully generate liver macrophage-specific gene knockout mice.41–43 We subjected Il-4rαfl/flClec4f-Cre+/− mice and WT littermates (Il-4rαfl/flClec4f-Cre−/−) to hepatic IR surgery and observed similar degrees of liver injury (figure 4G). However, liver regeneration was significantly delayed in the Il-4rαfl/flClec4f-Cre+/− mice, evidenced by larger areas of necrosis, higher Suzuki scores and lower numbers of Ki67+ hepatocytes than WT littermates (figure 4H–L). Interestingly, treatment of Il-4rαfl/flClec4f-Cre+/− mice with IL-4c did not improve liver repair (figure 4H–J), despite the presence of intact IL-4Rα on other cells. Taken together, these data demonstrate that the pro-repair effects of IL-4 after IR injury are mediated through IL-4Rα signalling in hepatic macrophages.

IL-4-induced HB-EGF production by hepatic macrophages plays an essential role in liver repair after IR injury

To further understand how IL-4/IL-4Rα signalling in hepatic macrophages contributes to tissue repair and regeneration after IR injury, we performed a Reverse Phase Protein Array (RPPA) experiment using liver samples harvested on day 3 after IR injury. The data revealed a reduced level of phosphorylated(p)-epidermal growth factor receptor (p-EGFR) in the liver of Il-4rαfl/flClec4f-Cre+/− mice compared with WT littermates (table 1). This result was confirmed by western blot analyses (figure 5A,B), and suggested that the IL-4/IL-4Rα signalling in hepatic macrophages could regulate one or more EGFR ligands. Thus, we purified hepatic macrophages from Il-4rαfl/flClec4f-Cre+/− mice and WT littermates on day 3 after IR injury and measured mRNA levels of all seven known EGFR ligands, including Egf, transforming growth factor alpha, Hb-egf, amphiregulin, epigen, epiregulin and betacellulin. The data showed that only the expression of Hb-egf was reduced in hepatic macrophages from Il-4rαfl/flClec4f-Cre+/− mice (figure 5C). To determine if IL-4, through IL-4Rα, directly triggers macrophages to produce HB-EGF, we treated bone marrow-derived macrophages (BMDM) from WT and Il-4rα−/− mice with IL-4. The data showed that IL-4 dramatically upregulated hb-egf mRNA and protein levels in WT-BMDM, but not in IL-4rα-deleted BMDM (figure 5D,E). Given our data showing that liver sinusoidal endothelial cell (LSEC) also express IL-4Rα (online supplemental figure S8), we isolated LSECs from naïve mice and treated them with IL-4. Interestingly, IL-4 did not induce hb-egf expression in LSECs (online supplemental figure S9), suggesting that IL-4/IL-4Rα-mediated signalling in LSECs does not significantly contribute to HB-EGF production. Taken together, these results suggest that (1) hepatic macrophages represent the predominant source of HB-EGF during liver IR injury and (2) the IL-4/IL-4Rα signalling is critical in HB-EGF production by macrophages.

Table 1

Proliferation-related proteins expression in the liver tissues from mice with hepatic macrophages-specific IL-4Rα deletion

Figure 5

IL-4/IL-4Rα signaling in hepatic macrophage induces HB-EGF expression. (A-C) Male Il-4rαfl/flClec4f-Cre+/- mice and WT littermates (Male Il-4rαfl/flClec4f-Cre-/-) were subjected to hepatic IR surgery and sacrificed after 3 days. Liver tissues were collected and hepatic macrophages were purified by magnetic-associated cell sorting (MACS) using anti-F4/80 antibody. (A, B) phospho(p)-EGFR and total (t)-EGFR protein levels in the liver tissue were detected by Western blotting and quantified (n=4/group). (C) mRNA levels of all EGFR ligands expressed by hepatic macrophages were measured by q-PCR (n=3/group). (D, E) WT-BMDM and Il-4rα-deleted BMDM were cultured with IL-4 for 6h or 24h. Control groups were treated with PBS (n=3/group). mRNA and protein levels of HB-EGF were measured at 6h by q-PCR and 24h by ELISA, respectively. (F-H) rmHB-EGF was i.p. injected to male Il-4rαfl/flClec4f-Cre+/- mice on day 1 and day 3 after liver IR surgery. Control mice were injected with PBS. All mice were sacrificed on day 7 after IR surgery (n=4/group). (F, G) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7. (H) Liver pathology was assessed by using the Suzuki’s scoring system. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in B, C, G and H. One-way ANOVA was performed in D and E.

Male Il-4rαfl/flClec4f-Cre+/− mice and WT littermates (male Il-4rαfl/flClec4f-Cre−/−) were subjected to hepatic IR surgery and sacrificed after 3 days. Liver tissue samples were processed and used for the RPPA screening.

To investigate the involvement of HB-EGF in tissue repair after IR injury, we injected recombinant mouse HB-EGF into Il-4rαfl/flClec4f-Cre+/− mice on days 1 and 3 after IR injury. As shown in figure 5F–H, exogenous HB-EGF restored liver repair by day 7 in these mice. To further determine whether HB-EGF produced by hepatic macrophages, rather than other cells, plays a critical role in liver repair, we generated a mouse with hepatic macrophage-specific deletion of hb-egf (Hb-egffl/flClec4f-Cre+/−). Figure 6A shows that these mice developed similar degrees of liver injury compared with WT littermates after IR surgery. However, whereas WT mice recovered by day 7 after IR injury, Hb-egffl/flClec4f-Cre+/− mice continued to show extensive areas of necrosis (>35% of the liver) with higher Suzuki scores (figure 6B–D). In line with this observation, hepatocyte proliferation, as quantified by Ki67 staining and hepatic PCNA expression, was also dramatically decreased in Hb-egffl/flClec4f-Cre+/− mice on day 3 after IR injury (figure 6E–H). In addition, western blot analyses showed that the p-EGFR levels were significantly lower in Hb-egffl/flClec4f-Cre+/− mice than WT littermates (figure 6I–J). Moreover, treatment of Hb-egffl/flClec4f-Cre+/− mice with IL-4c could not restore liver repair after IR injury (figure 6B–D), suggesting that the pro-repair function of IL-4 is dependent on hepatic macrophage-derived HB-EGF. Collectively, these data demonstrate that IL-4/IL-4Rα signalling in hepatic macrophages results in HB-EGF production which is essential in liver regeneration and repair after IR injury.

Figure 6

Liver repair after IR injury is impaired when hb-egf is deleted in hepatic macrophages. Male Hb-egffl/flClec4f-Cre+/-mice and WT littermates (Male Hb-egffl/flClec4f-Cre-/-) were subjected to hepatic IR surgery. After 24h, Hb-egffl/flClec4f-Cre+/- mice were divided into two groups and injected (i.p.) with PBS or IL-4c (n=6/group). (A) Serum ALT levels at 6h after IR surgery. (B, C) Liver necrosis (N, outlined areas) was evaluated and quantified on day 7 after IR surgery. (D) Liver pathology was assessed by using the Suzuki’s scoring system on day 7 after IR surgery. (E, F) Proliferative hepatocytes were stained for Ki67 and quantified on day 3 after IR surgery (n=4/group). (G, H) PCNA protein expression was detected by Western blotting and quantified. (I, J) p-EGFR and t-EGFR protein expression levels were detected by Western blotting and quantified. Two-tailed unpaired Student’s t-test with Welch’s correction was performed in A, F, H and J. One-way ANOVA was performed in C and D.

Discussion

The current studies demonstrate that eosinophils, persisting in the liver beyond the injury phase, orchestrate liver repair after IR injury and acute injury caused by APAP and CCl4. Eosinophil-derived IL-4, but not IL-13, activates hepatic macrophages through IL-4Rα signalling to produce HB-EGF, thereby facilitating hepatocyte proliferation.

Tissue repair after injury is a complex process critical for the survival of the organism. Subsets of innate immune cells are recruited to the wound site to clear debris and dead cells,44–46 triggering the proliferation of epithelial cells or progenitor cells47–50 and inducing vascularisation.51 The involvement of eosinophils in tissue repair has emerged as a previously unrecognised function. Recent studies of skeletal muscle injury, peritonitis and myocardial infarction have demonstrated the indispensable role of these cells in tissue repair.24–26 28–30 52 Our current study, using congenic and iPHIL mice and adoptive transfer of bmEos, provides the first evidence to support the indispensable role of eosinophils in liver repair after IR injury and in other models of acute liver injury, caused by APAP and CCl4. An observation common in the published studies and ours is that structural cell damage results in eosinophil infiltration to the injured tissues.31 53 This is probably because that injured tissues compel macrophages to release eotaxin-2 (CCL24), a crucial eosinophil chemoattractant,53 and type 2 innate lymphoid cells (ILC2s) are suggested to be potent inducers of eosinophil migration, either through their production of IL-5 or potentially through the production of eotaxin-1 (CCL11).54–56 In contrast, when cellular injury does not occur, such as in partial hepatectomy (PHx), we did not observe eosinophil infiltration to the liver (data not shown). However, there is one report describing that eosinophil-derived IL-4 could promote hepatocyte proliferation after PHx.39 Given that PHx causes intestinal perturbation, it is possible that eosinophils, which are abundant in the gut, may contribute to liver regeneration. The notion that IL-4 can directly stimulate hepatocyte proliferation is contradicted by another study of PHx,40 which showed that IL-4 did not directly affect hepatocyte proliferation. We generated mice with hepatocyte-specific IL-4Rα deletion to investigate if hepatocytes were a direct cellular target of IL-4. Our data ruled out this possibility and instead demonstrated that hepatocyte proliferation was attenuated when IL-4Rα was deleted in hepatic macrophages.

Macrophages are critically involved in the tissue repair process. A recent study of concanavalin A-induced acute liver injury demonstrated that hepatic macrophages encircled the necrotic areas to prevent further damage of hepatocytes and eventually eliminate necrotic lesions.57 It is known that macrophages adopt an inflammatory phenotype when they first enter an injured or infected tissue. They then switch to a pro-repair phenotype with the production of anti-inflammatory cytokines, growth factors and angiogenic factors.58–60 Although it is widely considered that macrophage activation through IL-4Rα contributes to tissue repair, the experimental evidence had been circumstantial. In vivo studies of macrophage-specific deficiency of IL-4Rα or identifying macrophage-derived pro-repair molecules are lacking. The current study filled a knowledge gap regarding how macrophage plasticity is regulated. Our data demonstrate that eosinophils play a crucial role, through IL-4, in promoting macrophages to produce HB-EGF that is necessary for liver repair after IR injury.

With regard to activating macrophages, IL-4 and IL-13 have been considered indistinguishable in promoting M2 polarisation.38 61 62 However, a more detailed investigation of downstream effects revealed differential gene targeting by IL-4 vs IL-13. Our data demonstrate that IL-4, but not IL-13, triggers HB-EGF production by macrophages. We also found that IL-4, but not IL-13 could rescue liver repair in ΔdblGATA1 mice. Antibody-mediated neutralisation of IL-4, but not IL-13, significantly delayed liver repair after IR injury in WT mice. Although IL-4 and IL-13 share the same receptor, IL-4Rα/IL-13Rα1, IL-4 is known to also bind to IL-4Rα/γc, which may contribute to the unique functions of IL-4. In congruent with our finding, several studies of tissue repair after myocardial infarction show the involvement of IL-4, but not IL-13.28–30 Another study of traumatic muscle wounds also showed that implantation of biomaterial scaffold induced a pro-regenerative response mediated by T helper 2 activation to produce IL-4.63

Through binding to EGF receptors, HB-EGF promotes cell proliferation, migration, adhesion and differentiation.64 Owing to these functions, HB-EGF has been implicated in wound healing and repair after injury in many tissues.65 In the liver during recovery from injuries, the level of HB-EGF is elevated.66 Studies of liver injury caused by CCl4, activation of Fas receptor or bile duct ligation show that HB-EGF treatment increases hepatocyte proliferation, decreases cell death and reduces areas of fibrosis.67–69 The current study provides the first evidence that HB-EGF plays a critical role in promoting liver repair after IR injury. More importantly, our data demonstrate that liver repair is significantly delayed when HB-EGF is specifically deleted from hepatic macrophages, suggesting that macrophages are a major source of HB-EGF. This is consistent with the fact that HB-EGF was first identified in the culture medium of human peripheral blood mononuclear cells.70 Further studies suggested that M2 polarised macrophages were a source of HB-EGF. For example, a head and neck cancer cell line (CAL17) co-cultured with M2 macrophages was resistant to radiation in an HB-EGF-dependent manner.71 Another in vitro study showed that co-culture with M2-polarised macrophages increased ovarian cancer cell proliferation and that this effect was abrogated by HB-EGF neutralising antibodies.72 A more recent in vivo study demonstrated that macrophages that infiltrated into the pancreas after cerulein-induced experimental pancreatitis produced high levels of HB-EGF. Importantly, this study showed that myeloid-specific HB-EGF deletion impaired DNA repair and decreased epithelial cell proliferation, resulting in delayed tissue recovery after pancreatic injury.73 It is known that HB-EGF is synthesised as a membrane-bound pro-HB-EGF, which is cleaved by a disintegrin and metalloprotease (ADAM) and matrix metalloproteinase, and the pro-inflammatory cytokine IL-1β to soluble HB-EGF.74 75 Although both pro-HB-EGF and soluble-HB-EGF can bind to the EGF receptor,65 76 a limitation of the current study is that we have yet to elucidate which form is at play. It may be possible that the IL-4/IL-4Rα signalling in macrophages is important in promoting HB-EGF synthesis and is involved in the shedding of pro-HB-EGF.

Another limitation of this study is the primary focus on hepatocyte proliferation during the liver repair process. It is important to recognise that the eosinophil-macrophage crosstalk may also impact other aspects of liver repair, such as resolving inflammation, remodelling extracellular matrix and promoting angiogenesis. These possibilities warrant further investigation in order to gain a better understanding of the pro-repair function of eosinophils.

In summary, we uncovered a previously unappreciated pro-repair function of eosinophils after hepatic IR injury. The experimental findings provided insights into the underlying mechanism of liver repair involving eosinophil and macrophage crosstalk through IL-4 signalling and HB-EGF production. There is currently no treatment modality to improve or accelerate tissue recovery after hepatic IR injury. Developing such a modality could enable the safe transplantation of ‘marginal’ livers and expand the donor organ pools. The current study provides strong evidence to further explore eosinophils and the IL-4/HB-EGF axis as novel approaches to improve the outcomes of liver transplantation and patients with acute liver injury.

Data availability statement

Data are available on reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Ethics statements

Patient consent for publication

Ethics approval

Not applicable.

References

Supplementary materials

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Footnotes

  • YY and LX contributed equally.

  • Correction notice This article has been corrected since it published Online First. The funding statement has been added.

  • Contributors YY designed and performed mouse experiments and various analyses. LX performed mouse experiments and flow cytometric analyses. YY prepared the figures and the manuscript. CA and LK performed immunohistochemical analyses. JZ, J-MJ, YW, NM, KHK, YAA, FW, SB, VV, BG and HKE reviewed and revised the manuscript. FB, RH and EJ generated and provided essential transgenic mouse lines. CJ conceptualised and supervised the study and revised the manuscript. CJ is the author responsible for the overall content as the guarantor.

  • Funding This work was supported by the National Institute of Health (NIH) DK121330, DK122796, and DK122708 and the University of Texas System Translational STARs award to CJ; the AST Research Network/CSL Behring Fellowship Basic Science Research grant to YY; National Institute of Health (NIH) HL154720, HL154720-03S1, HL165748, HL169519, DK122796, T32GM135118 and Department of Defense Grant W81XWH2110032 to HKE; AI132840-01A, DK121330, AI145108 and the Mayo Foundation grant to EAJ.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Linked Articles